Pancreatic Cancer Action

Team SAMBAI, TOUCH, The Black Breast Cancer Alliance, Named As Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024
Research, Women, Communications, African American, Health, Social Activism, Consumer, Science, Oncology, Breast cancer, Pancreatic Cancer Action, Incidence, Prostate Cancer UK, Survivor, BSN, Caregiver, Doctor of Philosophy, Prostate cancer, RN, MD, Education, Cancer Research UK, Prostate, National Cancer Institute, Breast, Safety, Organization, Patient, Ecosystem, Clinical trial, Factorization of polynomials, Team, Grand Challenges, Trust, Pancreatic cancer, Mortality, Morehouse School of Medicine, Cancer, Partnership, Pharmaceutical industry

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.
  • TOUCH, The Black Breast Cancer Alliance, as part of Team SAMBAI, is the first U.S.
  • Black-led breast cancer advocacy group to be an integral partner in the international Cancer Grand Challenge study.
  • Inequities in cancer prevention, screening, and treatment lead to disparities in cancer incidence and mortality and are a significant public health concern.

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Monday, June 26, 2023
Pancreatic cancer, Pancreatic Cancer Action, LAPC, FVC, Vital capacity, HIV disease progression rates, DMD, Patient, CD46, SAN, ADC, Pamrevlumab, MPH, IPF, Death, Idiopathic pulmonary fibrosis, Safety, Medical device, Pharmaceutical industry, Medical imaging, Vaccine, MD

SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to placebo and did not meet the primary endpoint of change from baseline in forced vital capacity (FVC) at week 48 (p=0.29). The mean decline in FVC from baseline to week 48 was 260 ml in the pamrevlumab arm compared to 330 ml in the placebo arm (placebo-corrected difference of 70 ml; 95% CI -60 to 190 ml). The secondary endpoint of time to disease progression (FVC percent predicted decline of ≥10% or death) was also not met (HR= 0.78; 95% CI 0.52 to 1.15).

Key Points: 
  • SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
  • Topline data from the LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory DMD patients expected 3Q 2023.
  • Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer (LAPC) expected 1H 2024.
  • Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 3 study of pamrevlumab in metastatic pancreatic cancer.

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

Retrieved on: 
Monday, November 7, 2022
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Molecule, Doctor of Philosophy, NYU, Patient, United Nations Scientific Committee on the Effects of Atomic Radiation, Tempus, Society for Immunotherapy of Cancer, Therapy, Neoplasm, NGS, CGMP, CEA, Section 32, Cell, Department, Consultant, HLA, Division, Immunotherapy, Annual general meeting, David Geffen School of Medicine at UCLA, Lung, Pancreatic cancer, UCLA, StepStone Group, MD Anderson Cancer Center, Oncology, Pancreatic Cancer Action, Medicine, Regent, Lung cancer, MSLN, Principal investigator, Cancer immunotherapy, Society, SITC, Poster, Mayo Clinic, Pharmaceutical industry, Medical imaging, Merck, MD, Schroders

Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02.

Key Points: 
  • Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02.
  • Once patients are identified, their T cells may be banked early in their disease course for potential utilization in a Phase 1 study in the event of relapse.
  • We are thrilled to enroll patients at BASECAMP-1 and get them prepped for potential inclusion in Phase 1 studies in 2023.
  • The Tmod mechanism utilizes two receptors to exploit common, specific gene losses in tumors that distinguish tumor from normal cells.

Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board

Retrieved on: 
Thursday, March 24, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Company, Mouse Models of Human Cancer database, Mirati, RAMP, Pancreatic cancer, National, Patent, BRAF, RHO, Â, CRAF, Government, National Cancer Institute, Patient, Oncogene, University of North Carolina academic-athletic scandal, Verastem Oncology, KRAS, Department of Defence, SEC, Doctor of Philosophy, Research, Coronavirus Scientific Advisory Board (Turkey), Cancer, MEK, Food, U.S. Securities and Exchange Commission, NSCLC, Security (finance), FAK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough therapy, RAS, Pancreatic Cancer Action, Science, Department, RAF, Lustgarten Foundation for Pancreatic Cancer Research, FDA, Oncology, ARAF, University, Chapel Hill, Amgen, Pharmaceutical industry, Aquaculture, Medical imaging, MD

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that Channing Der, PhD, has been appointed to its Scientific Advisory Board.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that Channing Der, PhD, has been appointed to its Scientific Advisory Board.
  • By joining Verastems Scientific Advisory Board, I look forward to contributing to the Companys efforts toward scientifically-driven breakthroughs for patients.
  • We are delighted that Dr. Der has joined our Scientific Advisory Board.
  • Dr. Der joins current Scientific Advisory Board members Robert Weinberg, PhD and Mario Sznol, MD.

Pancreatic Cancer Action Network (PanCAN) Funds Nearly $3 Million Of Innovative Research Through 2021 Grants Program

Retrieved on: 
Wednesday, July 14, 2021
Pancreatic Cancer Action Network, Pancreatic Cancer Action, Pancreatic cancer, Cancer, States of the United States, United States, Ralph H. Hruban

LOS ANGELES, July 14, 2021 /PRNewswire/ --The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, announced today the recipients of its 2021 research grants and grant extensions .

Key Points: 
  • LOS ANGELES, July 14, 2021 /PRNewswire/ --The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, announced today the recipients of its 2021 research grants and grant extensions .
  • Combined with its investment in leading-edge scientific and clinical initiatives, PanCAN's total research investment in fiscal year 2021 is $22 million, with nearly $3 million allocated to the Research Grants Program.
  • Learn more about PanCAN's research investments, visit pancan.org or follow the Pancreatic Cancer Action Network on Twitter , Instagram , and Facebook .
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

Cherry Creek Mortgage Holds Seventh Annual Fundraising Effort Supporting the Pancreatic Cancer Action Network

Retrieved on: 
Wednesday, July 7, 2021
Pancreatic Cancer Action Network, Pancreatic Cancer Action, Pancreatic cancer, Cancer, Cherry Creek, Causes of death, Medical specialties, United States

DENVER, July 7, 2021 /PRNewswire/ -- Cherry Creek Mortgage is celebrating its ongoing partnership with the Pancreatic Cancer Action Network (PanCAN) and recently hosted its seventh annual Swing for a Cure golf tournament to raise funds for the non-profit organization.

Key Points: 
  • DENVER, July 7, 2021 /PRNewswire/ -- Cherry Creek Mortgage is celebrating its ongoing partnership with the Pancreatic Cancer Action Network (PanCAN) and recently hosted its seventh annual Swing for a Cure golf tournament to raise funds for the non-profit organization.
  • "Our Cherry Creek Mortgage community has been directly affected by pancreatic cancer, and we are proud to honor the legacy of those we have lost by supporting PanCAN's life-saving mission."
  • "PanCAN is so fortunate to have Cherry Creek Mortgage as a long-time partner in the fight against pancreatic cancer.
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

The Pancreatic Cancer Action Network (PanCAN) Welcomes Two New Board Members And Scientific And Medical Advisory Board Chair

Retrieved on: 
Tuesday, July 6, 2021
Pancreatic Cancer Action Network, Pancreatic Cancer Action, Pancreatic cancer, United States

Each member has been personally touched by pancreatic cancer, including Argenti who lost his close friend and Temple who lost both her father and grandmother to the disease.

Key Points: 
  • Each member has been personally touched by pancreatic cancer, including Argenti who lost his close friend and Temple who lost both her father and grandmother to the disease.
  • He has been a passionate supporter of PanCAN since 2017 when his friend and bandmate, Matt Bencke, died from pancreatic cancer.
  • To learn more about PanCAN's board and scientific advisory leadership, visit pancan.org .
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

Pancreatic Cancer Action Network Rallies Survivors, Caregivers And Celebrities To Use Their Voice, Calling On Congress To Fund Research For World's Toughest Cancer

Retrieved on: 
Thursday, June 17, 2021
Cancer organizations, Pancreatic Cancer Action Network, Pancreatic Cancer Action, Cancer, National Cancer Institute, Pancreatic cancer

Nearly 2,000 participants tuned in from across the country to learn how to take action, marking the largest ever virtual gathering of pancreatic cancer advocates.

Key Points: 
  • Nearly 2,000 participants tuned in from across the country to learn how to take action, marking the largest ever virtual gathering of pancreatic cancer advocates.
  • The DOD's pancreatic cancer research program was created in 2019 as a direct result of PanCAN's advocacy efforts.
  • Additionally, advocates urgedCongress to fund $46.11 billion for the National Institutes of Health and for $7.6 billion for National Cancer Institute.
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform

Retrieved on: 
Wednesday, June 16, 2021
Clinical medicine, Drugs, Medicine, Orphan drugs, Pancreatic Cancer Action Network, Pancreatic cancer, Protein-bound paclitaxel, Gemcitabine, Pamrevlumab, Pancreatic Cancer Action, FOLFIRINOX, Devimistat

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise SM adaptive trial platform evaluating pamrevlumab [and standard of care] for patients with metastatic pancreatic cancer.

Key Points: 
  • SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise SM adaptive trial platform evaluating pamrevlumab [and standard of care] for patients with metastatic pancreatic cancer.
  • The new experimental treatment arm tests FibroGens pamrevlumab in combination with standard of care chemotherapy treatments for pancreatic cancer, gemcitabine and Abraxane.
  • PanCANs Precision Promise aims to revolutionize the clinical development paradigm in pancreatic cancer by enabling a faster, more efficient, and patient-centric approach to developing new treatment options and improving outcomes for pancreatic cancer patients.
  • For more information on the trial, please see clinical trials.gov: Precision Promise Trial
    The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

Star Trek's Kitty Swink, Armin Shimerman And Jonathan Frakes To Host Pancreatic Cancer Action Network's Voices In Action

Retrieved on: 
Monday, May 17, 2021
Pancreatic Cancer Action Network, Gastrointestinal cancer, Pancreatic cancer, Pancreatic Cancer Action, United States

b'LOS ANGELES, May 17, 2021 /PRNewswire/ -- Registration has officially opened for the Pancreatic Cancer Action Network\'s (PanCAN) Action Week Voices in Action event.

Key Points: 
  • b'LOS ANGELES, May 17, 2021 /PRNewswire/ -- Registration has officially opened for the Pancreatic Cancer Action Network\'s (PanCAN) Action Week Voices in Action event.
  • - Julie Fleshman, PanCAN\'s president & CEO\nPanCAN\'s Voices in Action is virtual, meaning anyone can participate and advocate to make a difference for pancreatic cancer patients and their families.
  • In 2021, more than 60,000 Americans will be diagnosed with pancreatic cancer and approximately 48,000 will die from the disease.
  • For more information on the Pancreatic Cancer Action Network and its urgent mission to save lives, visit pancan.org or follow PanCAN on Twitter , Instagram and Facebook .\n'